Allergan introduces REFRESH OPTIVE MEGA-3 enhanced with flaxseed oil
New offering restores lipid layer and brings hydration to all three layers of tear film damaged by Dry Eye.
Allergan has launched the over-the-counter (OTC) artificial tear REFRESH OPTIVE MEGA-3, the latest innovation in the REFRESH portfolio that fortifies the lipid layer when Meibomian Gland Dysfunction (MGD) patients suffer from Dry Eye. MEGA-3 is formulated with flaxseed and castor oil, two natural, plant-based oils which protect tears from evaporating while nourishing the lipid layer damaged by Dry Eye and providing essential hydration to all three layers of the tear film. It's clinically proven to treat the signs and symptoms of Dry Eye.
"I recommend MEGA-3 for patients suffering from Dry Eye symptoms associated with MGD, who are looking for relief. In addition, MEGA-3 is specially formulated for stability, so no shaking is required -- just drop and go." said Milton M. Hom, OD, FAAO.
An estimated 25 million people in the US suffer from Dry Eye symptoms, including irritation, blurred vision, sensitivity to light, burning, stinging, dryness and excessive tearing. MEGA-3 also contains carboxymethylcellulose (CMC), an active lubricant found in all REFRESH OPTIVE formulas. This water-loving polymer, binds to epithelial cells to maintain moisture on the ocular surface for rapid on-eye comfort and long-lasting relief."As the innovators of the number one doctor-recommended brand of artificial tears1, we are pleased to expand our robust dry eye portfolio with REFRESH OPTIVE MEGA-3," said Herm Cukier, Senior Vice President, Eye Care. "Our REFRESH line of patented products offer patients a wide variety of options to treat their individual dry eye needs."
All OPTIVE products include the patented osmoprotectant formula that includes three compatible solutes -- glycerin, I-carnitine and erythritol -- all of which deliver added protection to the corneal epithelial cells against hypertonic stress. REFRESH OPTIVE MEGA-3 contains a fourth osmoprotectant, trehalose, for an advanced approach to treating Dry Eye symptoms.
MEGA-3 is available in 30-count single-use vials and can be found nationwide at various retail locations where OTC eye drops are sold.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.